Diabetes insipidus and Langerhans cell histiocytosis: A case report of reversibility with 2-chlorodeoxyadenosine

Journal of Pediatric Hematology/Oncology

Volumn 25, Issue 7, 2003, Pages 575-577

  Ottaviano, Fabio ^b   Finlay, Jonathan L ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

2 chlorocleoxyadenosine; Diabetes insipidus; Langerhans cell histiocytosis

Indexed keywords

CLADRIBINE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TACROLIMUS; TIOGUANINE; VINBLASTINE;

ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CASE REPORT; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; DIABETES INSIPIDUS; HEAD AND NECK DISEASE; HISTIOCYTOSIS X; HUMAN; HUMAN TISSUE; INFANT; LABORATORY TEST; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

CLADRIBINE; DIABETES INSIPIDUS; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037972714     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200307000-00017     Document Type: Article

References (13)

1. Grois N, Flucher-Wolfram B, Heitger A, et al. Diabetes insipidus in Langerhans cell histiocytosis: Results from the DAL-HX 83 study. Med Pediatr Oncol. 1995;24:248-256.
2. Rosenszweig K, Arceci R, Tarbell N. Diabetes insipidus secondary to Langerhans' cell histiocytosis: Is radiation therapy indicated? Med Pediatr Oncol. 1997;29:36-40.
3. Titgemeyer C, Grois N, Minkov M, et al. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83 and 90 Study. Med Pediatr Oncol. 2001;37:108-114.
4. Leger J, Velazquez A, Garel C, et al. Thickened pituitary stalk on magnetic resonance imaging in children central diabetes insipidus. J Clin Endocrinol Metab. 1999;84:1954-1960.
5. Maghnie M, Genovese E, Bernasconi S, et al. Persistent high MR signal of the posterior pituitary gland in central diabetes insipidus. Am J Neuroradiol. 1997;18:1749-1752.
6. Broadbent V, Pritchard J. Diabetes insipidus associated with Langerhans cell histiocytosis: is it reversible? Med Pediatr Oncol. 1997;28:289-293.
7. Howarth D, Gilchrist G, Mullan B, et al. Langerhans cell histiocytosis: Diagnosis, natural history, management, and outcome. Cancer. 1999;85:2278-2290.
8. Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr. 2001;138:728-734.
9. Angeli SI, Alcalde J, Hoffman HT, et al. Langerhans' cell histiocytosis of the head and neck in children. Ann Otol Rhinol Laryngol. 1995;104:173-180.
10. Dunger DB, Broadbent V, Yeoman E, et al. The frequency and natural history of diabetes insipidus in children with Langerhans-cell histiocytosis. N Engl J Med. 1989;321:1157-1162.
11. Saven A, Burian C. Cladribine activity in adult Langerhans cell histiocytosis. Blood. 1999;93:4125-4130.
12. Grau J, Ribera JM, Tormo M, et al. Results of treatment with 2-chlorodeoxy-adenosine in refractory or relapsed Langerhans cell histiocytosis. Study of 9 patients. Med Clin (Barc). 2001;116:339-342.
13. Rajkumar SV, Burch PA, Nair S, et al. Phase II North Central Cancer Treatment Group study of 2-chlorodeoxyadenosine in patients with recurrent glioma. Am J Clin Oncol. 1999;22:168-171.